News
03-29-2012, 10:31 PM
ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology, today announced that Roche has announced positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial.
More... (http://www.news-medical.net/news/20120330/Positive-results-from-ImmunoGens-T-DM1-Phase-III-trial-on-HER2-positive-mBC.aspx)
More... (http://www.news-medical.net/news/20120330/Positive-results-from-ImmunoGens-T-DM1-Phase-III-trial-on-HER2-positive-mBC.aspx)